Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Immunovant Inc.

    NASDAQ: IMVT · Real-Time Price · USD
    14.71
    -0.11 (-0.74%)
    At close: Aug 20, 2025, 12:50 PM
    -0.74%
    Bid 14.7
    Market Cap 2.56B
    Revenue (ttm) 160K
    Net Income (ttm) -413.84M
    EPS (ttm) -2.84
    PE Ratio (ttm) -5.18
    Forward PE -5.44
    Analyst Buy
    Ask 14.72
    Volume 503,393
    Avg. Volume (20D) 1,292,041
    Open 14.80
    Previous Close 14.82
    Day's Range 14.50 - 14.99
    52-Week Range 12.72 - 34.47
    Beta 0.66

    About IMVT

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol IMVT
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for IMVT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts
    2 months ago
    +5.6%
    Immunovant shares are trading higher following a Q... Unlock content with Pro Subscription
    5 months ago
    +4.29%
    Immunovant shares are trading higher. B of A Securities and Guggenheim reiterated Buy ratings on the stock.
    news image

    4 days ago · seekingalpha.com

    Roivant Sciences: Vant Model And IMVT-1402 Create A 2025 Catalyst Stack

    Roivant Sciences Ltd.'s Vant model gives it risk-isolated development, monetization flexibility, and diversified optionality. ROIV's main value drivers are Immunovant, Priovant, Pulmovant, and Genevan...

    news image

    1 week ago · zacks.com

    Immunovant's Q1 Loss Narrower Than Expected, Pipeline in Focus

    IMVT reports a narrower Q1 loss, as spotlight remains on IMVT-1402's broad clinical potential across multiple indications.

    news image

    1 month ago · zacks.com

    All You Need to Know About Immunovant (IMVT) Rating Upgrade to Buy

    Immunovant (IMVT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

    news image

    1 month ago · zacks.com

    Wall Street Analysts See a 137.68% Upside in Immunovant (IMVT): Can the Stock Really Move This High?

    The mean of analysts' price targets for Immunovant (IMVT) points to a 137.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among anal...

    news image

    2 months ago · zacks.com

    Immunovant (IMVT) Upgraded to Buy: What Does It Mean for the Stock?

    Immunovant (IMVT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

    news image

    2 months ago · zacks.com

    IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus

    Immunovant stock rises on encouraging fourth-quarter fiscal 2025 results. It is on track to initiate 10 studies on IMVT-1402 across various autoimmune indications.

    news image

    3 months ago · businesswire.com

    IMVT INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into a Private Placement Transaction by Immunovant, Inc. and Encourages Investors to Contact the Firm

    SAN DIEGO--(BUSINESS WIRE)--Robbins Geller Rudman & Dowd LLP announces an investigation into potential breaches of fiduciary duty by the directors and officers of Immunovant, Inc. (NASDAQ: IMVT) and R...

    Add to Watchlist